iNCOVACC: A New Intranasal COVID-19 Vaccine for India

Bharat Biotech's intranasal COVID-19 vaccine, also known as iNCOVACC or BBV154, has been approved for use in India as a booster dose for those over 18 years of age. This needle-free vaccine will be available at private centers and has been introduced on the Co-WIN platform.

Eligibility for iNCOVACC

The iNCOVACC vaccine received approval from the Drugs Controller General of India in November for restricted use in an emergency situation as a booster dose for those over 18 years of age.

Availability of iNCOVACC

Those who have previously received the Covishield or Covaxin vaccines are eligible to receive iNCOVACC as a booster dose.

Benefits of the Nasal Spray Format

The vaccine will be available at private centers in India and has been introduced on the Co-WIN platform for distribution.

Potential Effectiveness of Nasal Vaccines

The nasal spray format of the iNCOVACC vaccine may trigger an immune response in the mucosal membranes, potentially providing local immunity in the upper respiratory tract and reducing infection and transmission. While data is not yet available to confirm this, the nasal spray format may provide more effective protection against transmission than current vaccines.

Practicality and Affordability of Nasal Vaccines

The convenience and affordability of the nasal spray format make it a practical choice for future vaccine development. It can be easily distributed and does not require cold chain storage at low temperatures. It has the potential to be developed as a multivalent vaccine, covering a wider spectrum of the SARS-CoV-2 virus.

Trials of iNCOVACC

The iNCOVACC vaccine was found to be "safe, well-tolerated, and immunogenic" in a phase III trial of nearly 3,100 participants in India, compared to Bharat Biotech's own Covaxin vaccine. The company has also conducted a trial with 875 participants to assess the use of iNCOVACC as a booster for those who have received Covaxin or Covishield as their primary vaccine.

Written by princy

No comments yet.

Leave a Reply